Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 12, 2007

Arteriosclerosis, Thrombosis, and Vascular Biology. 2007
Published online before print April 12, 2007, doi: 10.1161/ATVBAHA.107.142679
A more recent version of this article appeared on June 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/6/1411    most recent
ATVBAHA.107.142679v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Persson, M.
Right arrow Articles by Berglund, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Persson, M.
Right arrow Articles by Berglund, G.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Metabolic Syndrome

Submitted on November 13, 2006
Accepted on March 29, 2007

Elevated Lp-PLA2 Levels Add Prognostic Information to The Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

Margaretha Persson *; Bo Hedblad ; Jeanenne J. Nelson ; and Göran Berglund

From the Department of Clinical Sciences, Internal Medicine Research Group (M.P., G.B.) and Epidemiological Research Group (B.H.), University Hospital Malmö, Sweden; and Worldwide Epidemiology (J.J.N.), GlaxoSmithKline, Research Triangle Park, NC.

* To whom correspondence should be addressed. E-mail: margaretha.m.persson{at}skane.se.

Background--To explore potential interrelationships between lipoprotein-associated phosholipase A2 (Lp-PLA2), the metabolic syndrome (MetS), and incident cardiovascular disease (CVD).

Methods and Results--MetS was defined by the National Cholesterol Education Program Adult treatment Panel III criteria in 4480 nondiabetic Malmö Diet and Cancer Study subjects without history of CVD. Incidence of first CVD event (stroke [130 cases] or myocardial infarction [131]) was monitored over 10 years of follow-up. Lp-PLA2 activity and mass were significantly higher in subjects with MetS. Lp-PLA2 activity compared with Lp-PLA2 mass was more strongly correlated to individual components and increased more linearly with number of MetS components. Elevated Lp-PLA2 activity (top compared with bottom tertile), but not elevated Lp-PLA2 mass, increased risk for incident CVD (relative risk, RR: 1.54, 95% CI 1.07 to 2.24), as did MetS (1.42, 1.06 to 1.90) after taking possible confounders into account. Relative to those without either elevated Lp-PLA2 activity or MetS, combination of MetS and elevated Lp-PLA2 activity increased risk for CVD (1.97, 1.34 to 2.90). Elevated Lp-PLA2 activity without MetS increased risk for CVD (1.40, 1.03 to 1.92) but not MetS without elevated Lp-PLA2 activity (1.46, 0.94 to 2.27).

Conclusion--Lp-PLA2 is associated to the MetS. Higher plasma levels of Lp-PLA2 increased risk for incident CVD regardless of MetS. The simultaneous presence of elevated Lp-PLA2 activity and MetS may identify an especially high risk individual.
Key words: metabolic syndrome • cardiovascular risk • cohort study • Lp-PLA2




This article has been cited by other articles:


Home page
 Circ Heart FailHome page
T. Suzuki, C. Solomon, N. S. Jenny, R. Tracy, J. J. Nelson, B. M. Psaty, C. Furberg, and M. Cushman
Lipoprotein-Associated Phospholipase A2 and Risk of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study
Circ Heart Fail, September 1, 2009; 2(5): 429 - 436.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. G. Smith, C. Newton-Cheh, B. Hedblad, J. Struck, N. G. Morgenthaler, A. Bergmann, T. J. Wang, and O. Melander
Distribution and Correlates of Midregional Proadrenomedullin in the General Population
Clin. Chem., August 1, 2009; 55(8): 1593 - 1595.
[Full Text] [PDF]

Home page
 JAMAHome page
O. Melander, C. Newton-Cheh, P. Almgren, B. Hedblad, G. Berglund, G. Engstrom, M. Persson, J. G. Smith, M. Magnusson, A. Christensson, et al.
Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community
JAMA, July 1, 2009; 302(1): 49 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Tsimikas, J. Willeit, M. Knoflach, M. Mayr, G. Egger, M. Notdurfter, J. L. Witztum, C. J. Wiedermann, Q. Xu, and S. Kiechl
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study
Eur. Heart J., January 1, 2009; 30(1): 107 - 115.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. Wassertheil-Smoller, C. Kooperberg, A. P. McGinn, R. C. Kaplan, J. Hsia, S. L. Hendrix, J. E. Manson, J. S. Berger, L. H. Kuller, M. A. Allison, et al.
Lipoprotein-Associated Phospholipase A2, Hormone Use, and the Risk of Ischemic Stroke in Postmenopausal Women
Hypertension, April 1, 2008; 51(4): 1115 - 1122.
[Abstract] [Full Text] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.